Aesthetics Tech Forum 2025

January 9th & 10th, New Port Beach, CA

Octane’s Aesthetics Tech Forum is the premier event for physicians, industry professionals, investors, and entrepreneurs in the aesthetics technology space.

The Forum brings together thought leaders and innovators to explore cutting-edge medical aesthetic technologies, identify unmet clinical needs, and uncover new business opportunities.

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Symbio is thrilled to announce and share the recent press release from Jasper Therapeutics. We are incredibly proud to have been the CRO partner for this successful study. This achievement marks a significant milestone in our collaboration and commitment to advancing innovative therapies for the treatment of Urticaria and other mast cell-mediated diseases. Read full press release, “Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria”.

 

 

 

Symbio, Global Clinical Research Organization, Announces Two Key Leadership Appointments

January 13, 2025, New York, NY and Munster, Germany: Symbio, the global specialist therapeutic clinical research organization, is pleased to announce two key leadership appointments.

Shanna Smith is appointed Chief Commercial Officer. Shanna has a 16-year tenure with Symbio and brings an extensive background in crafting customer solutions in both clinical operations and commercial functions. She has played a pivotal role in driving Symbio’s growth and commitment to quality, building outstanding relationships with clients and investigators, and expanding Symbio’s global presence.

Patrick Ronan is appointed to the Board of Directors of Symbio. Patrick currently serves as an Operating Partner at ARCHIMED, a global investment firm focused on the healthcare industries. He is the former CEO of two life sciences firms, Validant (now Eliquent Life Sciences) and Greenleaf Health, which he founded in 2007. Prior to this, Patrick served as VP Regulatory Policy & External Affairs at Novartis and before that as Chief of Staff at the U.S. Food and Drug Administration (FDA), an executive role where he led the Agency on strategic, operational, and regulatory policy matters.

In a joint statement, Alan Morgan, Chief Executive, and Nick Thornton, Chairman said, “The high caliber of these appointments reflects Symbio’s commitment to bringing the highest levels of expertise to our clients’ development programs. We congratulate Shanna and Patrick and wish them much success and enjoyment in their new roles.”

 

Press queries contact:
Rose Panico, Symbio Director of Global Marketing
Office: +1-631-474-8531
Mobile: +1-516-994-6683
rose.panico@symbioresearch.com
symbioresearch.com

About Symbio

Symbio is a global specialist therapeutic CRO with exceptional expertise in Dermatology, Aesthetics, Wound Care, Ophthalmology, Inflammation, and Gastroenterology. The business operates across the USA and Europe, with additional expertise in Latin America, and Asia.

AAD 2024 in San Diego – What a Show!

As always, the AAD Annual Meeting was a resounding success. The Symbio team was able to meet with many clients and colleagues to discuss innovations in dermatology. It was great to see you all and we hope to connect again soon. Check out our photos and videos below.

AAD 2024 Video at the Show

You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

More Information

AAD 2024 Video at Happy Hour

You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

More Information